Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Transcript
What are the biggest management challenges in neuroendocrine tumors?
One of the bigger management challenges is access to care and access to specialists, ad that doesn’t mean that everyone needs to be managed by a NET specialist, because they absolutely don’t. But, I think all NET patients should at least be given the option of visiting with a NET specialist just to discuss the natural history of the disease and to discuss treatments that might be available, and I think also, at the time of progression, we should really try to get these patients to see a NET specialist to discuss the different treatment options out there, including clinical trials.
So, I think access to NET specialists, because there are not that many of them, is still an issue. Insurance is an issue for some agents, high copayments for certain agents. We have to see how things play out with PRRT [peptide receptor radionuclide therapy] and insurance reimbursement. But, that would be access and the financial toxicity or direct cost to the patient would be the things on the top of my mind.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More